Immuneering Corp
IMRX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001790340
No open-market purchases or sales by Immuneering Corp insiders were filed in the last 90 days; 111 institutions reported holding it in 13F filings for Q2 2026, worth $171.6M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Immuneering Corp insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Immuneering Corp, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Gengos Andrew | Chief Financial Officer | – | Jul 17, 2026 | 1 |
| Zeskind Benjamin J. | PRESIDENT AND CEO | 2,315,252 | Jun 24, 2026 | 2 |
| Hall Brett Matthew | CHIEF SCIENTIFIC OFFICER | 382,531 | Jun 16, 2026 | 3 |
| Carpenter Robert J | Director | 1,148,839 | Jun 11, 2026 | 1 |
| Schall Thomas J. | Director | 74,530 | Jun 11, 2026 | 2 |
| Hausman Diana | Director | 3,000Indirect | Jun 11, 2026 | 1 |
| Keating Laurie | Director | 14,000 | Jun 11, 2026 | 2 |
| Feinberg Peter | Director | 135,441Indirect | Jun 11, 2026 | 6 |
| Neufeld Leah R | CHIEF PEOPLE OFFICER | 29,598 | Mar 17, 2026 | 4 |
| Matushansky Igor | Chief Medical Officer | – | Feb 5, 2026 | 1 |
| Bookman Michael | CHIEF LEGAL OFFICER, SECRETARY | 4,870 | Feb 5, 2026 | 2 |
| Morales Mallory | SVP Finance, CAO | 27,533 | Feb 5, 2026 | 2 |
| Brakewood Harold Eugene | Chief Business Officer | 11,050 | Feb 5, 2026 | 2 |
| Berman Ann E | Director | 67,465 | Jun 16, 2025 | 0 |
| Cormorant Asset Management, LP | 10% Owner | 2,895,273Indirect | Apr 3, 2024 | 0 |
| Chen Bihua | 10% Owner | 2,895,273Indirect | Apr 3, 2024 | 0 |
| Cormorant Global Healthcare Master Fund, LP | 10% Owner | 2,895,273Indirect | Apr 3, 2024 | 0 |
| Cormorant Private Healthcare Fund III LP | 10% Owner | 2,895,273Indirect | Apr 3, 2024 | 0 |
| Barrett Scott | CHIEF MEDICAL OFFICER | 7,563 | Feb 17, 2023 | 0 |
| Amin Biren | CFO, TREASURER | 7,898 | May 12, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 14, 2026 (view filing) | Jan 12 | 2 days | Feinberg PeterDirector | PPurchaseClass A Common Stock | +20.0K | $4.35 | +$87.0K | +17.3%135.4K after | |
| Jan 15, 2026 (view filing) | Jan 13 | 2 days | Neufeld Leah RCHIEF PEOPLE OFFICER | PPurchaseClass A Common Stock | +2.63K | $4.15 | +$10.9K | +11.2%26.0K after | |
| Jan 16, 2026 (view filing) | Jan 15 | 1 day | Hall Brett MatthewCHIEF SCIENTIFIC OFFICER | PPurchaseClass A Common Stock | +2.30K | $4.57 | +$10.5K | +0.6%376.5K after | |
| Jan 20, 2026 (view filing) | Jan 15 | 5 days | Schall Thomas J.Director | PPurchaseClass A Common Stock | +21.6K | $4.67 | +$101.1K | +40.9%74.5K after | |
| Jan 21, 2026 (view filing) | Jan 16 | 5 days | Brakewood Harold EugeneChief Business Officer | PPurchaseClass A Common Stock | +5.25K | $4.76 | +$25.0K | +90.5%11.1K after | |
| Jun 16, 2026 (view filing) | Jun 15 | 1 day | Hall Brett MatthewCHIEF SCIENTIFIC OFFICER | PPurchaseClass A Common Stock | +6.04K | $4.15 | +$25.0K | +1.6%382.5K after | |
| Jun 24, 2026 (view filing) | Jun 23 | 1 day | Zeskind Benjamin J.PRESIDENT AND CEO | PPurchaseClass A Common Stock | +2.40K | $4.56 | +$10.9K | +0.1%2.32M after |